贝伐珠单抗治疗放射性坏死的剂量比较:肿瘤类型对水肿反应的影响
多中心回顾性队列研究纳入104例原发中枢神经系统肿瘤或脑转移患者,比较贝伐珠单抗7.5 mg/kg与10 mg/kg每三周给药对放射性坏死水肿反应的影响。未调整分析中7.5 mg/kg组水肿反应更优(p=0.032),但调整肿瘤类型后关联减弱;两组影像学反应无差异,7.5 mg/kg组临床反应更高(65.2% vs 37.8%,p=0.013)。
要点
- 两种剂量影像学反应相似,临床反应7.5 mg/kg组更高。
- 水肿反应差异在调整肿瘤类型后减弱。
- 不良事件、停药和再给药率两组相似。
核心结论
- 7.5 mg/kg与10 mg/kg贝伐珠单抗治疗放射性坏死 achieved similar radiographic outcomes。
- 调整肿瘤类型后水肿反应差异减弱,支持个体化给药。
研究设计与样本
- 多中心回顾性队列研究,纳入2021年6月至2024年7月接受贝伐珠单抗治疗放射性坏死的成人原发中枢神经系统肿瘤或脑转移患者104例。
- 按剂量分组:7.5 mg/kg组n=53,10 mg/kg组n=51,每三周给药。
- 主要终点为盲法神经肿瘤学家评估的水肿反应。
主要发现
- 两组肿瘤类型分布差异显著(p<0.001),10 mg/kg组原发中枢神经系统肿瘤更多。
- 未调整分析中水肿反应两组差异有统计学意义(p=0.032), favoring 7.5 mg/kg组;调整肿瘤类型后关联减弱。
- 对比增强病灶反应在未调整或调整分析中均无差异(p=0.43)。
- 临床反应7.5 mg/kg组更高(65.2% vs 37.8%,p=0.013)。
- 不良事件、治疗中断和再给药率两组相似。
关键数值与推荐
- 水肿反应未调整分析p=0.032, favoring 7.5 mg/kg组。
- 对比增强病灶反应p=0.43。
- 临床反应7.5 mg/kg组65.2% vs 10 mg/kg组37.8%,p=0.013。
临床怎么用
- 贝伐珠单抗7.5 mg/kg与10 mg/kg均可考虑用于放射性坏死,影像学结局相似。
- 临床决策应结合肿瘤类型个体化选择剂量。
局限性
- 回顾性研究设计。
- 两组肿瘤类型分布差异显著,可能混杂水肿反应结果。
- 样本量104例,需前瞻性肿瘤分层研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Bevacizumab is an effective treatment for radiation necrosis; however, dose -dependent radiographic and edema response data are lacking. METHODS: Multicenter, retrospective cohort study of adult patients with primary central nervous system (CNS) tumors or brain metastases who received bevacizumab for radiation necrosis between June 2021 and July 2024. Patients were grouped by bevacizumab dose (7.5 mg/kg vs. 10 mg/kg administered every three weeks). Primary outcome was edema response, assessed by a blinded neuro-oncologist. Secondary outcomes included contrast enhancing disease response, clinical response, adverse events, treatment discontinuation, and re-dosing for recurrent radiation necrosis. Analyses were performed with and without adjustment for tumor type. RESULTS: 104 patients were included (7.5 mg/kg, n = 53; 10 mg/kg, n = 51). Tumor type differed significantly between cohorts (p < 0.001), with more primary CNS tumors in the 10 mg/kg group. Edema response differed between dosing groups in unadjusted analyses (p = 0.032), favoring the 7.5 mg/kg cohort; however, this association was attenuated after adjustment for tumor type. Contrast enhancing disease response did not differ between groups in either unadjusted or adjusted analyses (p = 0.43). Clinical response was higher in the 7.5 mg/kg group (65.2% vs. 37.8%, p = 0.013). Rates of adverse events, treatment discontinuation, and re-dosing were similar. CONCLUSIONS: Taken together, both 7.5 mg/kg and 10 mg/kg dosing strategies achieved similar radiographic outcomes. Prospective, tumor-stratified studies incorporating edema-focused and patient-centered endpoints are needed to better define optimal dosing strategies in this heterogeneous population. These findings support an individualized approach to bevacizumab dosing in radiation necrosis and highlight the need for prospective, tumor-stratified studies.
引用
- Schultz SE, Labib M, Breit J, et al. Comparative dosing of bevacizumab for radiation necrosis: impact of tumor type on edema response. J Neurooncol. 2026. PMID: 42859298. doi:10.1007/s11060-026-05826-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。